Nov 2026· Molecular Medicine· Vol 32· 0 citations· 245 references
Medicine
TL;DR
Emerging evidence reveals that the TME acts as an important factor in driving CRC progression by regulating the immune system through dynamic cellular and molecular interactions, and will enhance biomarker discovery and aid in developing precision medicine for patients with CRC.
Abstract
Colorectal cancer (CRC) is a heterogeneous disease that results from the progressive accumulation and interactions at multiple levels of genetic alterations, which lead to the transformation of normal colonic epithelium into malignant colorectal tumors. Understanding the molecular basis of CRC pathogenesis, together with the interactions between genetic alterations, epigenetic modifications, environmental and lifestyle factors, is essential for improving prevention, diagnosis, prognosis, and treatment strategies. This review aims to provide a critical reference point for understanding the temporal dynamics of colorectal carcinogenesis, the evolution of molecular classification systems, including their computational and machine-learning foundations and emerging image-based prediction approaches, molecular drivers and the tumor microenvironment (TME) of CRC by summarizing the most investigated molecular pathways involved in CRC pathogenesis and their role as biomarkers for early CRC diagnosis based on the three main molecular mechanisms of colorectal carcinogenesis: chromosomal instability (CIN), microsatellite instability (MSI), and CpG island methylator phenotype (CIMP). Importantly, emerging evidence reveals that the TME acts as an important factor in driving CRC progression by regulating the immune system through dynamic cellular and molecular interactions. In particular, tumor metabolic reprogramming and microbiota-driven alterations act as major drivers of therapy resistance and immune escape. Combining these mechanisms will enhance biomarker discovery and aid in developing precision medicine for patients with CRC. This review also highlights the regulatory roles of key signaling pathways, including Wnt/β-catenin, epidermal growth factor receptor (EGFR), tumor protein p53 (TP53), and transforming growth factor-beta (TGF-β) signaling, during CRC initiation and progression, while further addressing current targeted therapies and emerging precision-based and experimental therapeutic strategies.
Colorectal cancer (CRC) remains one of the most common malignancies worldwide and a leading cause of cancer-related mortality. Recent advances in CRC molecular biology have focused on biomarkers for early detection, prognostic stratification, treatment selection, and disease monitoring. Clinically validated biomarkers,...
Katarzyna Herbetko, Aleksandra Herbetko, Sara Suwała et al.· Cells· 0 citations
Colorectal cancer (CRC) remains one of the most frequently diagnosed malignancies worldwide, and colorectal cancer liver metastasis (CRLM) represents a major cause of CRC‐related mortality. The liver provides a highly specialized environment that can be remodeled into a metastatic niche, where anatomical structure, met...
Jia-Liang Fan, Hui-Ru Zhang, De-Yang Kong et al.· MedComm· 0 citations
Colorectal cancer (CRC) ranks third in global incidence and second in cancer-related mortality, with the liver constituting the most frequent target organ for metastatic dissemination and distant organ involvement representing the predominant cause of death. Approximately 20–25% of patients present with synchronous hep...
Rui-Qing Zhang, Jie-Ni Qu, Hong-Fang Chi et al.· Frontiers in Immunology· 0 citations
Epigenetic mechanisms play a significant role in breast cancer (BC) pathogenesis and contribute to the tumor’s progression, metastasis and resistance to therapy. BC heterogeneity in large part is determined by unique epigenetic landscape created by various factors. However, despite obvious heterogeneity, modern therape...
E. Asanova, L. Khakimova, I. Golovkin et al.· Advances in Molecular Oncolo...· 0 citations
Continued research is therefore required to improve prevention, diagnosis and treatment outcomes, and tumour heterogeneity, treatment resistance and the difficulty of preventing cancer at population level remain important challenges.
S. M, N. N· International journal of com...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.